news 3 Preferred status = fewer barriers to start therapy Adalimumab biosimilars: Faster access, same standard of care What is adalimumab used for? Adalimumab is a TNF-alpha inhibitor used across multiple specialties, including: ■Rheumatology (RA, PsA, AS) ■Dermatology (plaque psoriasis, HS) ■Gastroenterology (Crohn’s, UC) ■Ophthalmology (uveitis) These conditions often require consistent long-term therapy. Are biosimilars the same as generic biologics? Biosimilars are not “generic biologics” … but they are clinically equivalent. ■Highly similar to Humira® ■Expected to have no clinically meaningful differences in: —Effectiveness —Safety —Immunogenicity FDA-labeled indications for preferred biosimilar products Humira Hadlima Hulio Simlandi Rheumatoid arthritis (RA) Plaque psoriasis Crohn’s disease Ulcerative colitis (UC) Psoriatic arthritis (PsA) Hidradenitis suppurativa (HS) Ankylosing spondylitis (AS) Juvenile idiopathic arthritis Fewer prior authorization requirements. Faster claim approval at the pharmacy. Fewer treatment delays. Smoother prescribing workflow. Earlier therapy initiation. Improved adherence / continuity. Fewer interruptions from coverage issues. Better overall treatment experience. For Providers, preferred status may mean: For patients, preferred status may mean: Several adalimumab biosimilars approved by the U.S. Food and Drug Administration (FDA) are now designated as preferred products on the Texas Medicaid Preferred Drug List. Rx Rx Non-PDLPA Covered Delays Start therapy Gaps Outcomes when nonpreferred products are prescribed Outcomes when preferred products are prescribed Adalimumab Biologics Adalimumab biosimilars offer the same clinical expectations as the reference product, while preferred formulary placement may support faster access and fewer administrative delays—helping patients start and stay on therapy.
RkJQdWJsaXNoZXIy MjI2MTU5NA==